RE: dead moneyI am disappointed that MPH didn't bounce nicely on the exposure recently in New York. It is another reminder that drug development is a long term business and filled with more risk and speculation than sales and profits, which ultimately are the only things that will sustain a company. I am still holding but was going to halve my holdings if I got to a double which for me is at 1.00. I am content to wait to hear the next announcement regarding a partnerhship but the news may be slow after that. The one unpredictable factor is the interest of the biotech investment community that may want take a shine to MPH.